Integrin receptor antagonists
    5.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号:US06358970B1

    公开(公告)日:2002-03-19

    申请号:US09599088

    申请日:2000-06-21

    IPC分类号: A61K31435

    摘要: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

    摘要翻译: 本发明涉及其化合物及其衍生物,其合成及其作为整联蛋白受体拮抗剂的用途。 更具体地说,本发明的化合物是整联蛋白受体α2和/或阿尔巴博5的拮抗剂,可用于抑制骨吸收,治疗和预防骨质疏松,抑制血管再狭窄,糖尿病性视网膜病变,黄斑变性,血管生成,动脉粥样硬化,炎症, 炎症性关节炎,病毒性疾病,癌症和转移性肿瘤生长。